Treatment considerations for primary myelofibrosis.
Biemond
B J
BJ
D000740:Anemia / Q000188:drug therapy / Q000209:etiology; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D006801:Humans; D000077269:Lenalidomide; D054438:Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative / Q000188:drug therapy / Q000401:mortality / Q000628:therapy; D009389:Neovascularization, Pathologic; D055728:Primary Myelofibrosis / Q000188:drug therapy* / Q000401:mortality / Q000628:therapy; D011379:Prognosis; D012307:Risk Factors; D013792:Thalidomide / Q000031:analogs & derivatives / Q000627:therapeutic use
D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D013792:Thalidomide; D000077269:Lenalidomide